Journal profile · Psychiatry
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
ISSN 0278-5846 · eISSN 1878-4216 · Elsevier Inc. · ENGLAND · Bimonthly · Founded 1982
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.18; hybrid open access; APC about USD 4,380; median 100 days to acceptance (119 articles, last 24 months); community-reported acceptance: about 50%; 332 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY is published by Elsevier Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neurotransmitter Receptor Influence on Behavior, Tryptophan and brain disorders and Neuroscience and Neuropharmacology Research, together about 29.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject.Progress in Neuro-Psychopharmacology & Biological Psychiatry - Psychedelics is a special section dedicated to research on psychedelics. Within this special section, the journal aims to publish reviews and research papers dealing with experimental and clinical aspects of psychedelics. More specifically, work describing mechanisms of action and pharmacological aspects of psychedelics as well as their effects on the nervous system is welcome.Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated. Bibliometric analysis studies will not be considered.
From the journal's Aims & Scope
Research area (LetPub): Psychiatry
Editor-in-chief Louis GendronPublisher website
Editorial board by country: 4 in mainland China (about 9%); most named United States 11, Canada 8, Mainland China 4, United Kingdom 2, South Korea 2 (46 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neurotransmitter Receptor Influence on BehaviorNeuroscience11.6%
- Tryptophan and brain disordersNeuroscience8.8%
- Neuroscience and Neuropharmacology ResearchNeuroscience8.8%
- Schizophrenia research and treatmentMedicine7.9%
- Stress Responses and CortisolNeuroscience7.4%
- Bipolar Disorder and TreatmentMedicine5.4%
- Treatment of Major DepressionMedicine4.9%
- Functional Brain Connectivity StudiesNeuroscience4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Psychiatry | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Psychiatry | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Psychiatry | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.18LetPub ·
- Impact factor (publisher)
- 4.2Publisher website ·
- CiteScore 2026-06
- 6.5LetPub ·
- CiteScore (publisher)
- 6.5Publisher website ·
- SJR 2026-06
- 1.5LetPub ·
- SNIP 2026-06
- 1.2LetPub ·
- h-index
- 114LetPub ·
- h-index
- 189OpenAlex ·
- i10-index
- 5,526OpenAlex ·
- 2-year mean citedness
- 3.68OpenAlex ·
- Self-citation rate
- 2.4%LetPub ·
- Share of gold OA articles
- 26.79%LetPub ·
Volume
- Articles per year
- 313LetPub ·
Articles by year OpenAlex count · 8,396 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 336 | 108 | 100 |
| 2025 | 332 | 137 | 1,110 |
| 2024 | 277 | 110 | 2,271 |
| 2023 | 176 | 75 | 2,556 |
| 2022 | 155 | 62 | 3,221 |
| 2021 | 214 | 87 | 6,509 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
100 daysMedian, submission to acceptance · P25–P75 61 days – 170 days
- Acceptance to online
- median 2 days (119 articles)
- Submission to online
- median 103 days
- Sample
- 119 articles with submission and acceptance dates (805 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Submission to first decision
- 38 daysPublisher website ·
- First decision after review
- 91 daysPublisher website ·
- Submission to acceptance
- 149 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,380 / EUR 4,100 / GBP 3,510 / JPY 543,250 | — | — | |
| Publisher website | USD 4,070 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteWhat to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Author–date
- Highlights
- Required
- Graphical abstract
- Optional
- Not considered
- Bibliometric analysis studies; biological extracts
Article types accepted3
- original research articles1. Original research articlesLength not stated
- registered reports3. Registered Reports This journal supports Registered Reports as article type, allowing you to have your research reviewed and pre-registered prior to conducti…Length not stated
- review articles2. Review articles Mini-reviews or comprehensive reviews of cutting edge work, or syntheses of cutting edge work that has been done in the past two years.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1982
- ISSN
- 0278-5846
- Electronic ISSN
- 1878-4216
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
What CAS zone is PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY in?
In the 2025 upgraded edition of the CAS Journal Ranking, PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY is in Zone 2 of Medicine, and in Zone 2 of the minor category Clinical Neurology / Neurosciences / Pharmacology & Pharmacy / Psychiatry. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY?
The latest impact factor listed by LetPub is 4.18; CiteScore 6.5, h-index 189.
How long does peer review take at PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY?
Based on the dates recorded on 119 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 100 days (interquartile range 61–170 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Author–date; Highlights: Required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY based?
Of the 46 board members whose country the journal's board page names, 4 (about 9%) are in mainland China; the countries named most often are United States (11), Canada (8) and Mainland China (4). Counted from the institutions listed on the board page; for reference only.
Which databases index PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY?
According to LetPub and DOAJ records, PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY is indexed in SCIE and Scopus.
Is PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY open access, and what is the APC?
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY is a hybrid journal. For open-access publication: APC about USD 4,380.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .